by Treatment Options Targeting Brain’s Thermostat Lead to Innovations in Non-hormonal Drugs
High prevalence of fluctuating estrogen levels and depleting musculoskeletal health among women are some of the key drivers contributing to the robust growth of the menopausal hot flashes treatment market. Hence, healthcare companies are increasing their clinical trials in non-hormonal products to meet various cases. Recently, in January 2020, the U.K.-based clinical-stage biotech company KaNDy Therapeutics, announced positive data of their Phase 2b “SWITCH-1” clinical trial of their novel lead non-hormonal drug candidate, NT-814, for the treatment of menopause. Though the hormonal treatment type segment is expected to lead the menopausal hot flashes treatment market, non-hormonal treatment type segment is anticipated for exponential growth during the forecast period.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111711
Companies in the market for menopausal hot flashes are increasing R&D in treatment options that target the brain’s thermostat to reduce incidence of hot flashes in women. Such innovations are creating value-grab opportunities for companies in the market menopausal hot flashes treatment market, whilst improving the quality of life of postmenopausal women.
Femtech to Explore Untapped Potential in Women’s Midlife Health Issues
The menopausal hot flashes treatment market is expected to grow at a CAGR of 6% during the forecast period. Most women from Generation X are now in their 40s and are technologically proficient. Likewise, online drug sales is anticipated to flourish in the market for menopausal hot flashes. However, there is a lack of interest from the femtech toward solving the issues of women’s midlife health issues.
The femtech sector has been more active toward solving the issues of menstrual health and pregnancy. However, there is a growing need for attention toward women’s midlife health issues such as menopausal hot flashes. Hence, companies are exploring untapped opportunities to address the stigma and associated silence pertaining to symptoms of menopause.
Companies in the menopausal hot flashes treatment market are targeting digitally literate women to create awareness about the issues related to menopause through social media. They are increasing their efficacy in complementary and alternative medicine (CAM) for management of hot flashes.
Innovations in Devices Attract Healthcare Companies
Apart from innovations in medicines, companies in the menopausal hot flashes treatment market are recommending women toward lifestyle modifications through online media channels. Likewise, companies are developing cutting-edge devices that suit the needs of women. For instance, the introduction of the Menopod™ has led to the growth of market for menopausal hot flashes, owing to its compact computer mouse-like shape and portability. The advent of smartwatch-like devices that act as a personal thermostat for women is also driving the global market.
Due to high prevalence of tech-savvy women in their late 40s, companies in the market for menopausal hot flashes are unearthing value opportunities with the development of mobile apps. These mobile apps are providing healthcare companies with important insights about the frequency of hot flashes in women. On the other hand, companies in the menopausal hot flashes treatment market are increasing research in customizable mattresses that offer cooling and heating temperature controls.
Cognitive Behavior Therapy Proves Effective in Addressing Complications Associated with Hot Flashes
The demand for nonpharmacologic treatment options is projected to escalate in the menopausal hot flashes treatment market. Thus, healthcare providers are adopting cognitive behavior therapy to improve menopause symptoms. This novel therapy is being highly publicized for not only treating hot flashes, but is also effective for other menopause symptoms. Companies in the menopausal hot flashes treatment market are creating awareness about cognitive behavior therapy, owing to its advantages of modifying dysfunctional emotions, behaviors and thoughts that enhance personal coping strategies. Since researchers have gained clinical success with the help of cognitive behavior therapy for the treatment of anxiety and depression, healthcare companies are expanding their healthcare services using the novel therapy.
Complications associated with menopausal hot flashes such as sleep disturbances and low-productivity levels in professional environments are increasing the demand for cognitive behavior therapy among patients. Long-term effectiveness of cognitive behavior therapy post treatment are creating lucrative opportunities for healthcare providers. Thus, healthcare companies are increasing efforts to conduct large-scale clinical trials in order to analyze its effectiveness in highly symptomatic women.
Analysts’ Viewpoint
Apart from innovations in medicines, alternative options such as weight-training and lifestyle modifications are proving to be effective for hot flashes. The hormone replacement therapy is highly popular in the menopausal hot flashes treatment market. However, controversies encircling the risk of blood clots, stroke, and some cancers pose a barrier for market growth. Hence, companies should tap opportunities in alternative treatment options such as cognitive behavior therapy, which is not only effective in the management of hot flashes, but also treats other symptoms such as anxiety and sleep disorders. Digitalization of health is another key driver contributing toward market growth, as femtech can target tech-savvy women through social media and innovative mobile apps.
Menopausal Hot Flashes Treatment Market: Overview
Menopause is defined as the permanent cessation of menses that may occur in as early as the thirties or as late as the sixties. The treatment and management of menopausal women has been a matter of great apprehension in the last few decades, both in terms of epidemiology and medical scientific research.
The most common menopausal symptoms, including vasomotor symptoms (menopausal hot flashes), insomnia, vaginal atrophy, altered cognitive function, dementia, depression, and loss of muscle mass, can affect up to 80% of women during menopause and may be severe in up to 20% of these women
Menopausal hot flashes symptoms treatment drugs are used to reduce hot flashes, which is a form of temperature dysfunction that occurs due to changes in gonadal hormones. Menopausal hot flashes symptom treatments are classified into hormonal treatment, non-hormonal treatment, and alternative treatment (including herbal products).
Hormonal treatment products are available in different dosage forms such as pill, patch, and gel. The use of hormone replacement therapy (HRT) alleviates menopausal hot flashes symptoms and leads to a major improvement in quality of life for women with menopausal hot flashes symptoms.
Growing population of elderly women worldwide coupled with rise in menopausal hot flashes symptoms is a major factor responsible for the growth of global menopausal hot flashes treatment market
Increase in awareness about women’s health due to different public as well as private organizations initiatives is also fueling the growth of global menopausal hot flashes treatment market
Moreover, development of advanced products with alternative mode of administration and changes in lifestyle associated with early menopause are some of the major factors attributed for the growth of global menopausal hot flashes treatment market
Market Segmentation: Menopausal Hot Flashes Treatment Market
Based on treatment type, the global menopausal hot flashes treatment market has been divided into hormonal treatment, non-hormonal treatment, and alternative treatment
Hormonal treatment is further classified into estrogen, progesterone, and estrogen – progesterone combination
The non-hormonal segment is sub-segmented into antidepressant, gabapentin, pregabalin, and clonidine. Antidepressant is further divided into Paroxetine, Fluoxetine, Vanlafaxine, Desvanlafaxine, and others.
The alternative segment is further sub-divided into black cohosh, vitamin E, herbal medicines, and others
Based on distribution channel, the global menopausal hot flashes treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies
Each of the segments has been analyzed in detail for global menopausal hot flashes treatment market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
The global menopausal hot flashes report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with menopausal hot flashes market size estimations.
Regional Overview: Menopausal Hot Flashes Treatment Market
In terms of region, the global menopausal hot flashes treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
The current and future market sizes for menopausal hot flashes treatment market in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027
The study also offers a list of recommendations, highlights, and useful insights of the global menopausal hot flashes treatment market which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process
Major Players
The global menopausal hot flashes report concludes with the company profiles section that includes key information about the major players in the market
Key players analyzed in this global menopausal hot flashes treatment market include –
- Pfizer Inc.
- Novartis AG
- Novo Nordisk A/S
- Allergan plc
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Hisamitsu Pharmaceutical Co., Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc
- TherapeuticsMD, Inc
Each of these players has been profiled in the menopausal hot flashes treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Menopausal Hot Flashes Treatment Market Report
- What is the sales/revenue generated by each treatment type segment of the menopausal hot flashes treatment market across all regions during the forecast period?
- What are the opportunities in the global menopausal hot flashes treatment market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which region is likely to expand at the fastest CAGR during the forecast period?
- Which menopausal hot flashes treatment type and distribution channel segments are expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
- What is the market share or position of different companies operating in the global market in 2018?
Menopausal Hot Flashes Treatment Market – Segmentation
Treatment Type
- Hormonal Treatment
- Estrogen
- Progesterone
- Estrogen-Progesterone Combination
- Non-hormonal Treatment
- Antidepressant
- Paroxetine
- Fluoxetine
- Venlafaxine
- Desvenlafaxine
- Others
- Gabapentin
- Pregabalin
- Clonidine
- Alternative Treatment
- Black Cohosh
- Vitamin E
- Herbal Medicines
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111711/2900
